All In Biotech

Drug Trial Radar · NCT06444867

A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968

An Open-label, Phase 1b, Multi-site Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following a Single Dose of LEO 158968 in Subjects With Gout Flares

Last checked: Nov 20, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Jan 7, 2025

Primary completion

Sep 18, 2025

Study completion Sep 18, 2025

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Jun 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the study is to evaluate the effect on pain of a single, subcutaneous (SC) dose of LEO 158968 in participants with gout flares.

Conditions

  • Joint Pain
  • Gout Flares
  • Joint Inflammation

Interventions

  • LEO 158968Drug

    SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with a Patient-reported Pain Intensity Score of 0 or 1 as Assessed by the 5-point Likert Scale on Day 4Time frame: Day 4

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • LEO Pharma Investigational Site

    Lille, France

  • LEO Pharma Investigational Site

    Venlo, Netherlands

  • LEO Pharma Investigational Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.